This department is offering the grant to conduct original research on the function of neoantigens and neoepitopes in type 1 diabetes, particularly focusing on post-translational modifications and autoimmune responses. The goal is to enhance understanding of the disease’s etiology and pathophysiology, improve disease monitoring tools, and potentially develop personalized therapeutics. Proposals should integrate new discoveries with existing knowledge of autoantibodies like insulin, GAD65, IA-2, and ZnT8. Applications are welcomed from institutions for this grant that does not require a clinical trial.
Opportunity ID: 332178
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DK-21-004 |
| Funding Opportunity Title: | The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Food and Nutrition Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 17, 2021 |
| Last Updated Date: | Mar 17, 2021 |
| Original Closing Date for Applications: | Mar 09, 2022 |
| Current Closing Date for Applications: | Mar 09, 2022 |
| Archive Date: | Apr 14, 2022 |
| Estimated Total Program Funding: | $2,000,000 |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses County governments State governments Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) encourages applications from institutions and organizations proposing original research aimed at the characterization of the function of neoepitopes and neoantigens in type 1 diabetes. This includes the function that post-translational modifications might have in the humoral and cell mediated autoimmune responses and overall in the etiology and pathophysiology of type 1 diabetes. Proposals that include the discovery of neoantigens or neoepitopes are within the scope of this solicitation, but should propose a plan for integrating these discoveries with the present knowledge on established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8). In the long-term the goals of this initiative are to facilitate the development of better tools to monitor disease progression and treatment, and potentially to facilitate the development of personalized therapeutics. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-004.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 332178 Full Announcement-RFA-DK-21-004 -> RFA-DK-21-004-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00265974 | May 22, 2021 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00269865 | Oct 28, 2021 | Mar 09, 2022 | View |
Package 1
Mandatory forms
332178 RR_SF424_2_0-2.0.pdf
332178 PHS398_CoverPageSupplement_5_0-5.0.pdf
332178 RR_OtherProjectInfo_1_4-1.4.pdf
332178 PerformanceSite_2_0-2.0.pdf
332178 RR_KeyPersonExpanded_2_0-2.0.pdf
332178 PHS398_ResearchPlan_4_0-4.0.pdf
332178 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
332178 RR_Budget_1_4-1.4.pdf
332178 RR_SubawardBudget30_1_4-1.4.pdf
332178 PHS398_ModularBudget_1_2-1.2.pdf
332178 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
332178 RR_SF424_5_0-5.0.pdf
332178 PHS398_CoverPageSupplement_5_0-5.0.pdf
332178 RR_OtherProjectInfo_1_4-1.4.pdf
332178 PerformanceSite_4_0-4.0.pdf
332178 RR_KeyPersonExpanded_4_0-4.0.pdf
332178 PHS398_ResearchPlan_4_0-4.0.pdf
332178 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
332178 RR_Budget_3_0-3.0.pdf
332178 RR_SubawardBudget30_3_0-3.0.pdf
332178 PHS398_ModularBudget_1_2-1.2.pdf
332178 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
